SION

Sionna Therapeutics Inc

Add to Watchlist

Advanced Chart

19.100

-0.04(-0.209%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

19.530

Open

19.530

VWAP

18.82

Vol

70.23K

Mkt Cap

842.78M

Low

18.210

Amount

1.32M

EV/EBITDA(TTM)

Total Shares

44.12M

573.11M

EV/OCF(TTM)

P/S(TTM)

Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.

3 Analyst Rating

101.57% Upside

Wall Street analysts forecast SION stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SION is 38.50 USD with a low forecast of 32.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

101.57% Upside

Current: 19.100

Low

32.00

Averages

38.50

High

45.00

101.57% Upside

Current: 19.100

Low

32.00

Averages

38.50

High

45.00

The End

See All Ratings

No Data

Valuation Metrics

The current forward P/E ratio for Sionna Therapeutics Inc (SION.O) is -7.99, compared to its 5-year average forward P/E of -5.32. For a more detailed relative valuation and DCF analysis to assess Sionna Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.32

Current PE

-7.99

Overvalued PE

-3.10

Undervalued PE

-7.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.63

Current EV/EBITDA

-4.37

Overvalued EV/EBITDA

-2.26

Undervalued EV/EBITDA

-7.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

FY2025Q1

YoY :

+49.53%

-19.66M

Operating Profit

FY2025Q1

YoY :

+39.12%

-16.48M

Net Income after Tax

FY2025Q1

YoY :

+32.14%

-0.37

EPS - Diluted

FY2025Q1

YoY :

+24.28%

-16.37M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

20.1M

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SION News & Events

Events Timeline

2025-06-04 (ET)

2025-06-04

07:05:23

Sionna Therapeutics announces data from Phase 1 trials of SION-719, SION-451

2025-05-12 (ET)

2025-05-12

07:14:44

Sionna Therapeutics sees cash runway into 2028

2025-05-12

07:14:29

Sionna Therapeutics reports Q1 EPS (62c), consensus (45c)

News

2.0

07-02Benzinga

Hut 8, Greenbrier And Other Big Stocks Moving Higher On Tuesday

9.0

06-04Newsfilter

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

1.0

06-03Newsfilter

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference